News

Lassman Law+Policy Placed on LMG Life Sciences Shortlist of "Regulatory Firms to Watch"

Lassman Law+Policy recently was honored by LMG Life Sciences by being placed on its "Shortlist" of Regulatory Firms to Watch in 2019. Lassman Law+Policy is the only boutique firm specializing in FDA regulatory law to be recognized in that category. Congratulations to the other nominees: Akin Gump, Debevoise & Plimpton, and Mayer Brown!

LMG Life Sciences evaluates attorneys on the basis of case evidence, peer feedback and client feedback.

Categories: Honors

Chambers USA: America’s Leading Lawyers for Business Recognizes Scott Lassman

Scott Lassman recently was honored by Chambers USA: America’s Leading Lawyers for Business. Mr. Lassman was named a Ranked Lawyer for 2019 in the area of Pharmaceutical/Medical Products Regulatory law.

The Chambers rankings are determined by independent research into a range of qualities and evidence of an attorney's work.

Categories: Honors

Biosmilars

Scott Lassman spoke on Biosimilars at the Food and Drug Law Institute’s Introduction to Biologics and Biosimilars Conference in Washington, D.C.

Categories: Speaking

The First Amendment: Recent Developments and Impacts on Industry

Scott Lassman spoke on First Amendment issues at the Food and Drug Law Institute's Advertising and Promotion for Medical Products Conference in Washington, D.C.

Categories: Speaking

Hatch-Waxman and BPCIA Overview

Scott Lassman spoke on the Biologics Price Competition and Innovation and Hatch-Waxman Acts at ACI's FDA Boot Camp in Boston.

Categories: Speaking

Scott Lassman Named to 2018 LMG Life Sciences' Stars List

Scott Lassman was named to this year's LMG Life Sciences’ Stars list, which recognizes outstanding U.S. legal practitioners with a focus on the life sciences industry. Mr. Lassman was recognized in the regulatory practice areas of FDA Medical Device, Healthcare Pricing & Reimbursement, and FDA Pharmaceutical law.

LMG Life Sciences evaluates attorneys on the basis of case evidence, peer feedback and client feedback.

Categories: Honors

GRx+Biosims 2018

Scott Lassman spoke on New Biosimilar Developments at the GRx+Biosims 2018 conference in Baltimore.

Categories: Speaking

NYC MedTech Conference

Scott Lassman spoke on biopharma regulatory issues at the NYC MedTech Conference in New York, NY. The conference was a medical technology life science forum hosted by the Consulate General of Hungary in New York.

Categories: Speaking

Chambers USA: America’s Leading Lawyers for Business Recognizes Scott Lassman

Scott Lassman has been honored by Chambers USA: America’s Leading Lawyers for Business. Mr. Lassman is a 2018 Recognised Practitioner in the area of Pharmaceutical/Medical Products Regulatory law.

The Chambers rankings are determined by independent research into a range of qualities and evidence of an attorney's work.

Categories: Honors

Scott Lassman Named to 2016 LMG Life Sciences' Stars List

Scott Lassman was named to the LMG Life Sciences’ Stars list, which recognizes outstanding U.S. legal practitioners with a focus on the life sciences industry. Mr. Lassman was recognized for his work in regulatory law.

LMG Life Sciences evaluates attorneys on the basis of case evidence, peer feedback and client feedback.

Categories: Honors

Scott Lassman

Scott M. Lassman's Profile Image
Scott Lassman has nearly 30 years’ experience in FDA law and policy, both as an in-house attorney and in private practice. He provides strategic advice and advocacy to small, mid-size and large pharmaceutical, biotechnology and medical device companies, as well as the trade associations that represent them and the investors who fund them. His practice covers all aspects of FDA regulatory law, with a special focus on exclusivity, biosimilars, product approval and policy matters...

Read More About Scott

For More Information

  • This field is for validation purposes and should be left unchanged.